160 related articles for article (PubMed ID: 35931468)
1. Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Kumar A; Wang C; Sheedy SP; McCauley BM; Winham SJ; Ramus SJ; Anglesio MS; Kim B; Torres D; Keeney GL; Cliby WA; Goode EL
Gynecol Oncol; 2022 Sep; 166(3):508-514. PubMed ID: 35931468
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
Torres D; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Wang C; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):223-227. PubMed ID: 30503050
[TBL] [Abstract][Full Text] [Related]
3. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Torres D; Wang C; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Konecny GE; Goode EL; Cliby WA
Gynecol Oncol; 2018 Aug; 150(2):227-232. PubMed ID: 29925470
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
Torres D; Kumar A; Wallace SK; Bakkum-Gamez JN; Konecny GE; Weaver AL; McGree ME; Goode EL; Cliby WA; Wang C
Gynecol Oncol; 2017 Dec; 147(3):503-508. PubMed ID: 28964622
[TBL] [Abstract][Full Text] [Related]
6. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
7. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
9. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
[TBL] [Abstract][Full Text] [Related]
10. [Value of computed tomography in the staging and predicting resectability of primary advanced ovarian carcinoma].
Lou FL; Shi YF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):701-5. PubMed ID: 17274380
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
12. Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
Nasser S; Lazaridis A; Evangelou M; Jones B; Nixon K; Kyrgiou M; Gabra H; Rockall A; Fotopoulou C
Gynecol Oncol; 2016 Nov; 143(2):264-269. PubMed ID: 27586894
[TBL] [Abstract][Full Text] [Related]
13. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
15. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
16. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
[TBL] [Abstract][Full Text] [Related]
18. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
De Decker K; Wenzel HHB; Bart J; van der Aa MA; Kruitwagen RFPM; Nijman HW; Kruse AJ
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):246-256. PubMed ID: 36734363
[TBL] [Abstract][Full Text] [Related]
19. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.
Foster KI; Handley KF; Glassman D; Sims TT; Javadi S; Palmquist SM; Saleh MM; Fellman BM; Fleming ND; Bhosale PR; Sood AK
Int J Gynecol Cancer; 2023 Jun; 33(6):937-943. PubMed ID: 36948527
[TBL] [Abstract][Full Text] [Related]
20. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
